

CTLA4 & PDCD1 Research Grade Lorigerlimab

Catalog No.	DHD17208A DHD17208B	Quantity:	100 µg 1.0 mg
Alternate Names:	Tetavalent Bispecific, MGD 019, MGD-019, MGD019 CAS: 2416595-46-3		
Description:	Research Grade Lorigerlimab is a tetavalent bispecific Human/humanized monoclonal antibody that targets human Cytotoxic T-lymphocyte protein 4 (CTLA-4, CD152) and Programmed cell death protein 1 (CD279)		
UniProt ID (target):	P16410 & Q15116		
Specificity:	Human CTLA-4 (CD152) and PD-L1 (CD279)		
Concentration:	1.0 mg/ml, lot specific		
Source:	XtenCHO cell line		
Isotype:	Human [V-kappa'-VH-h-CH2-CH3_V-kappa-VH'] ₂		
Formulation:	0.01M PBS buffer, pH 7.4		
Purity:	> 95% by SDS-PAGE		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Protein A/G affinity chromatography		
Applications:	Functional studies		
INN:	Lorigerlimab		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.